Therapeutic uses of tri-, tetra-, penta-, and polypeptides
AssigneeInnapharma, Inc.
InventorsHenry B. Abajian, Joseph J. Hlavka, John P. Feighner
Life of this patent
Estimating the term…
Abstract
Novel uses of certain peptides to treat patients suffering from neurological or psychiatric disorders are disclosed. The peptides include the tripeptide hormone MIF and compounds made by modifications of MIF, such as modification of amino terminus residues, carboxyl terminus residues and internal residues, including addition and substitution of amino acid residues and modification of the peptide bonds and functional side groups of respective amino acid residues. The tri-, tetra-, penta-, peptides and polypeptides may be utilized alone or in combination with other agents, to treat patients suffering from physiological, psychosomatic, neurological or psychiatric disorders.
Claims16
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (7c):
- R1-AA1-R1-Pro1-AA1-Gly-Trp (7c)
- wherein Pro1 represents the amino acid Pro;
- AA1 represents the amino acid Phe;
- AA2 represents the amino acid homo-Arg;
- and R1 and R2 each independently are selected from the group consisting of a hydrogen atom, a halogen atom, and a hydroxyl group.
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (7d):
- R1-AA1-R2-Pro1-AA2-Gly-AA3-R (7d)
- wherein Pro1 represents an amino acid selected from the group consisting of Pro and Dehydro-Pro;
- AA1 represents an amino acid selected from the group consisting of Phe, PhenylGly and Tyr;
- AA2 represents the amino acid Arg;
- AA3 represents an amino acid selected from the group consisting of Trp and AzaTrp;
- R1 and R2 each independently are selected from the group consisting of a hydrogen atom, a lower alkyl group having 1 to 3 carbon atoms, at least one halogen atom, a hydroxyl group, a sulphydryl group, an alkylamino group, and a diakylamino group, and R is selected from the group consisting of an amino group and a hydroxylamino group.
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (7e):
- R1-AA1-R2—Pro1-AA2-Gly-R4-Trp-NH2 (7e)
- wherein Pro1 represents the amino acid Pro;
- AA1 represents the amino acid Phe;
- AA2 represents the amino acid Arg;
- R1 and R2 each independently are selected from the group consisting of a hydrogen atom;
- at least one halogen atom and a hydroxyl group;
- and the tryptophan residue is modified at one of C4, C5, C6 and C7, with R4 selected from the group consisting of a halogen atom, a hydroxyl group, and an alkyl group.
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (7f):
- R1-AA1-R2—Pro1-R5-AA2-Gly-Trp-NH2 (7f)
- wherein Pro1 represents the amino acid Pro;
- AA1 represents the amino acid Phe;
- AA2 represents the amino acid Leu;
- R1 and R2 each independently are selected from the group consisting of a hydrogen atom, at least one halogen atom and a hydroxyl group;
- and R5 represents at least one halogen atom.
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (7g):
- R1-AA1-R2—Pro1-AA2-Gly-R4-AA3-R (7g)
- wherein Pro1 represents an amino acid selected from the group consisting of Pro and Dehydro-Pro;
- AA1 represents the amino acid Phe;
- AA2 represents the amino acid Arg;
- AA3 represents the amino acid Trp;
- R1 and R2 each independently are selected from the group consisting of a hydrogen atom and at least one halogen atom;
- and R4 is selected from the group consisting of at least one halogen atom, a hydroxyl group, a methyl group, and a methoxy group.
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (12):
- R1-Phe-R2-Arg-Gly-Trp-NH2 (12)
- wherein R1 represents a halogen atom and R2 represents a carboxylic acid of a monocyclic organic compound, with a three to six member ring structure having a hetero nitrogen atom.
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one pentapeptide or salt thereof having a general formula (13):
- R1-Phe-AA1-Arg-Gly-Trp-NH2 (13)
- wherein R1 represents a halogen atom, and AA1 represents an amino acid selected from the group consisting of 1-amino-1-carboxycyclopentane and 1-amino-1-carboxycyclopropane.
A method for treating a physiological, psychosomatic, neurological or psychiatric disorder in a patient, comprising administering to the patient at least one a pentapeptide having a general formula (10):
- R1-AA1-R2—Pro1-AA2-AA4-Gly-AA3-R (10)
- where Pro1 represents the amino acid dehydro-Pro;
- AA1 represents the amino acid Phe;
- AA2 represents the amino acid Arg;
- AA3 represents the amino acid Trp;
- AA4 represents the amino acid Gly;
- R is selected from the group consisting of a carboxyl group, a hydroxyalkyl group, a carbamyl group, an alkylcarbamyl group, and an alkoxycarbonyl group;
- and, R′ and R2 each independently are selected from the group consisting of a hydrogen atom, a lower alkyl group, a halogen atom, a hydroxyl group, a sulphydryl group, an alkylamino and a dialkylamino group.
Dependencies are inferred from the claim text.